Non-invasive imaging of hypoxia — challenges and opportunities

Molecular Imaging Probes for Cancer Research

Volumn , Issue , 2012, Pages 285-313

  Koch, C J ^a   Evans, S M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY;

NON-INVASIVE IMAGING;

MOLECULAR PHYSICS;

EID: 84986587197     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789814293686_0010     Document Type: Chapter

References (120)

1. Ballinger JR. Imaging hypoxia in tumors. Seminars Nucl. Med. 2001; 31: 321–329.
2. Rajendran JG, Schwartz DL, O’Sullivan J, PETerson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA. Tumor hypoxia imaging with [F-18]Fluoromisonidazole Positron Emission Tomography in head and neck cancer. Clin. Cancer Res. 2006; 12: 5435–5441.
3. Couturier O, Luxen A, Chatel J-F, Vuillez J-P, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur. J. Med. Mol. Imag. 2004; 31: 1182–1206.
4. Gerweck LE, Zaidi ST, Zeitman A. Multivariate determinants of radiocurability I: prediction of single fraction tumor control doses. Int. J. Radiat. Oncol. Biol. Phys. 1994; 29: 57–66.
5. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of the Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J. Nuc. Med. 2007; 48: 471–480.
6. Koch CJ. Measurement of Absolute Oxygen Levels in Cells and Tissues using Oxygen Sensors and the 2-nitroimidazole EF5. Meth. Enzymol. Antioxidants and Redox Cycling 2002; 353: 3–31.
7. Evans SM, Schrlau A, Chalian AA, Zhang P, Koch CJ. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding. J. Invest Dermatol 2006; 126: 2596–2606.
8. Evans SM, Judy KD, Dunphy I, Jenkins WT, Hwang W-T, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, Collins RA, Koch CJ. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin. Cancer Res. 2004; 10: 8177–8184.
9. Evans SM, Fraker DL, Hahn SM, Gleason K, Jenkins WT, Jenkins K, Hwang W-T, Zhang PD, Mick R, Koch CJ. EF5 binding and clinical outcome in human soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 922–927.
10. Evans SM, Du KL, Chalian AA, Mick R, Zhang PJ, Hahn SM, Quon H, Lustig R, Weinstein GS, Koch CJ. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 1024–1031.
11. Alper T, Howard-Flanders P. Role of oxygen in modifying the radiosensitivity of E. Coli B. Nature 1956; 178: 978–979.
12. Koch CJ. ComPETition Between Radiation Protectors and Radiation Sensitizers in Mammalian Cells. Radioprotectors and Anticarcinogens 1983; 275–296.
13. Koch CJ. The mechanism of radioprotection by non-protein sulfhydryls: cysteine, Glutathione and Cysteamine. Bump EA and Malaker K. (Eds.), pp. 25–52. CRC Press Inc, Boca Raton, Florida, 1998.
14. Koch CJ, Howell RL. Combined radiation-protective and radiation-sensitizing agents II. radiosensitivity of hypoxic or aerobic Chinese hamster fibroblasts in the presence of cysteamine and misonidazole: implications for the “oxygen effect” (with appendix on calculation of dose-modifying factors). Radiat. Res. 1981; 87: 265–283.
15. Horan A-M, Koch CJ. The Km for radiosensitization by oxygen is much greater than 3 mm of Hg and is further increased by elevated levels of cysteine. Radiat. Res. 2001; 156: 388–398.
16. Kallinowski F, Zander R, Hockel M, Vaupel P. Tumor tissue oxygenation as evaluated by computerized- pO2-histography. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 953–961.
17. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer 1955; 9: 539–579.
18. Bush RS, Jenkins RD T, Allt WEC, Beale FA, Bean H, Dembo AJ, Pringle JF. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer 1978; 37: 302–306.
19. Moulder JE, Rockwell SC. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 1984; 10: 695–712.
20. Chapman JD, Franko AJ, Koch CJ. The fraction of hypoxic clonogenic cells in tumor populations. Biological Bases and Clinical Implications of Tumor Radioresistance 1983; 61–73.
21. Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radioth. Oncol. 1985; 3: 97–115.
22. Fowler JF. Chemical modifiers of radiosensitivity theory and reality: a review. Int. J. Radiat. Oncol. Biol. Phys. 1985; 11: 665–674.
23. Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Noll L, Hancock S, Phillips TL. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. Int. J. Radiat. Oncol. Biol. Phys. 1990; 18: 389–393.
24. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 1994; 6: 509–518.
25. Hockel M, Knoop C, Schlenger K, Vordran B, Baussmann E, Mitze M, Knapstein PG, Vaupel P. Intratumor pO2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology 1993; 26: 45–50.
26. Stone HB, Brown JM, Phillips TL, Sutherland RM. Oxygen in human tumors: correlations between methods of measurement and response to therapy. Radiat. Res. 1993; 136: 422–434.
27. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol. Radioth. & Oncol. 1998; 46: 135–146.
28. Radioprotectors: chemical, Biological, and Clinical PerSPECTives. 1998.
29. Koch CJ, Evans SM. Cysteine concentrations in rodent tumors: unexpectedly high values may cause therapy resistance. Int. J. Cancer 1996; 67: 661–667.
30. Moreno-Merlo F, Nicklee T, Hedley DW. Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts. Brit. J. Cancer 1999; 81: 989–993.
31. Workman P. Pharmacokinetics of hypoxic cell radiosensitizers. Cancer Clin. Trials 1980; 3: 237–251.
32. Koch CJ, Hahn SM, Rockwell KJ, Covey JM, McKenna WK, Evans SM. Pharmacokinetics of the 2-nitroimidazole EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide] in human patients: implications for hypoxia measurements in vivo. Cancer Chemoth. Pharmacol. 2001; 48: 177–187.
33. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S. Prognostic significance of [18F]- misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of trans-Tasman Radiation Oncology Group Study 98.02. J. Clin. Oncol. 2006; 24: 2098–2104.
34. Sauer LA, Dauchy RT. Regulation of lactate production and utilization in rat tumors in vivo. J. Biol. Chem. 1985; 260: 7496–7501.
35. Saunders MI, Dische S, Fermont D, Bishop A, Lenox-Smith I, Allen JG, Malcolm SL. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study. Brit. J. Cancer 1982; 46: 706–710.
36. Koch CJ, Stobbe CC, Hettiaratchi P. Combined radiation-protective and radiation-sensitizing agents: IV Measurement of intracellular protector concentrations. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 1025–1027.
37. Walton MI, Bleehen NM, Workman P. The reversible N-oxidation of the nitroimidazole radiosensitizer Ro 03-8799. Biochem. Pharmacol. 1985; 34: 3939–3940.
38. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EO. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Brit. J. Cancer 2004; 90: 2232–2242.
39. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DYW, Chou S-C, Raleigh JA. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker. Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 592–602.
40. Tannock IF. Oxygen diffusion and the distribution of radiosensitivity in tumours. Br. J. Radiol. 1972; 45: 515–524.
41. Evans SM, Jenkins WT, Shapiro M, Laughlin K, Chan C, Koch CJ. Evaluation of the concept of “hypoxic fraction” as a descriptor of tumor oxygenation status. Oxygen Transport to Tissue, XVIII. Adv. Exptl. Biol. Med. 1997; 215–225.
42. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important than the “hypoxic fraction” in determining tumor response to fractionated radiation therapy. Radiat. Res. 1997; 147: 541–550.
43. Suit HD, Goitein M, Munsenrider JE, Verhey L, Gragoudas E, Koeler AM, Urano M, Shipley WU, Linggood RM, Friedberg C, Wagner M. Clinical experience with proton beam radiation therapy. J. Can. Assoc. Radiol. 1980; 31: 35–39.
44. Koch CJ. The unusual dependence on oxygen concentration of toxicity by SR-4233 [3- amino-1,2,4-benzotriazine-1,4-dioxide]: an hypoxic cell toxin. Cancer Res. 1993; 53: 3992–3997.
45. Mohindra JE, Rauth AM. Increased killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 1976; 36: 930–936.
46. Sridhar R, Koch CJ, Sutherland RM. Cytotoxicity of two nitroimidazole radiosensitizers in an in vitro tumor model. Int. J. Radiat. Oncol. Biol. Phys. 1976; 1: 1149–1157.
47. Varghese AJ, Gulyas S, Mohindra JK. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)- 3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 1976; 36: 3761–3765.
48. Chapman JD. Hypoxic sensitizers implications for radiation therapy. New Eng. J. Of Med. 1979; 301: 1429–1432.
49. Iyer RV, Haynes PT, Schneider RF, Movsas B, Chapman JD. Marking hypoxia in rat prostate carcinomas with b-D-[125I] azomycin galactopyranoside and [99mTc]HL-91: correlation with microelectrode measurements. J. Nucl. Med. 2001; 42: 337–344.
50. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J. Nucl. Med. 2008; 49: 129S–148S.
51. Miller GG, Best MW, Franko AJ, Koch CJ, Raleigh JA. Quantitation of hypoxia in multicellular spheroids by video image analysis. Int. J. Radiat. Oncol. Biol. Phys. 1989; 16: 949–952.
52. Hodgkiss RJ, Jones G, Long A, Parrick J, Smith KA, Stratford MRL. Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection. Br. J. Cancer 1991; 63: 119–125.
53. Lord EM, Harwell LW, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 1993; 53: 5271–5276.
54. Varia MA, Calkins-Adams DP, Rinker LH, Kennedy AS, Novotny DB, Fowler WC, Raleigh JA. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecologic Oncol. 1998; 71: 270–277.
55. Dolbier WR, Li A-R, Koch CJ, Shiue C-Y, Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure. Appl. Rad. and Isot. 2001; 54: 73–80.
56. Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [F-18]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg. Med. Chem. 2001; 9: 665–675.
57. Wardman P. Molecular structure and biological activity of hypoxic cell radiosensitizers and hypoxic specific cytotoxins. Advanced Topics on Radiosensitizers of Hypoxic Cells, 49–75, 1982.
58. Raleigh JA, Koch CJ. The importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 1990; 40: 2457–2464.
59. Koch CJ, Raleigh JA. Radiolytic reduction of protein and non-protein disulfides in the presence of formate: a chain reaction. Arch. Biochem. Biophys. 1991; 287: 75–84.
60. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat. Res. 1990; 122: 301–308.
61. Koch CJ. The reductive activation of nitroimidazoles; modification by oxygen and other redox-active molecules in cellular systems. Selective Activation of Drugs by Redox Processes. NATO Series A 1990; 198: 237–247.
62. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1Himidazol- 1-yl)-N-(2,2,3,3,3-pentafluoroproply)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br. J. Cancer 1995; 72: 869–874.
63. Koch CJ. Importance of Antibody Concentration in the Assessment of Cellular Hypoxia by Flow Cytometry: EF5 and Pimonidazole. Radiat. Res. 2008; 169: 677–688.
64. Chapman JD, LEE, J, Meeker BE. Adduct formation by 2-nitroimidazole drugs in mammalian cells: optimization of markers for tissue oxygenation. Selective Activation of Drugs by Redox Processes. NATO Series A 1990; 198: 313–323.
65. Joseph P, Jaiswal K, Stobbe CC, Chapman JD. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. Int. J. Rad. Onc. Biol. Phys. 1994; 29(2): 351–355.
66. Siim BG, Menke DR, Dorie MJ, Brown JM. Tirapazamine-induced cytotoxicity and DNA damage in trasplanted tumors: relationship to tumor hypoxia. Cancer Res. 1997; 57: 2922–2928.
67. Dennis MF, Stratford MR, Wardman P, et al. Cellular uptake of misonidazole and analogues with basic or acidic functions. Int. J. Radiat. Oncol. Biol. Phys. 1985; 47: 629–643.
68. Rasey JS, Krohn KA, Freauff S. Bromomisonidazole: synthesis and characterization of a new radiosensitizer. Radiat. Res. 1982; 91: 542–554.
69. Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, Krohn KA. Characterization of radiolabelled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 1987; 111: 292–304.
70. Wiebe LL, Stypinski D. Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. Quart. J. Nuc. Med. 1996; 40: 270–284.
71. Saitoh J-I, Sakuri H, Suzuki Y, Muramatsu H, Ishikawa H, Kitamoto Y, Akimoto T, Hasegawa M, Mitsuhashi N, Nakano T. Correlations between in vivo tumor weight, oxygen pressure, 31P NMR SPECTroscopy, hypoxic microenvironment marking by b-D-iodinated azomycin galactopyranoside (b-D-IAZGP), and radiation sensitivity. Int. J. Radiat. Oncol. Biol. Phys. 2002; 54: 903–909.
72. Parliament MB, Chapman JD, Urtasun RC, McEwan AJ, Golberg L, Mercer JR, Mannan RH, Wiebe LI. Non-invasive assessment of human tumour hypoxia with I-iodoazomycin arabinoside: preliminary report of a clinical study. Br. J. Cancer 1992; 65: 90–95.
73. Rajendran JG, Schwartz DL, O’Sullivan J, PETerson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA. Hypoxia and glucose metabolism in malignant tumors: evaluation by 18F-fluoromisonidazole and 18F-fluorodeoxyglucose positron emission tomography imaging. Clin. Cancer Res. 2004; 10: 2245–2252.
74. Gronroos T, Eskola O, Lehtio K, Minn H, Marjamaki P, Bergman J, Haaparanta M, Forsback S, Solin O. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J. Nucl. Med. 2001; 42: 1397–1404.
75. Tewson TJ. Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nuc. Med. & Biol. 1997; 24: 755–760.
76. Rasey JS, Hofstrand PD, Chin LK, Tewson TK. Characterization of [18F]Fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J. Nuc. Med. 1999; 40: 1072–1079.
77. Grosu A-L, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V, Hans-Jurgen W, Reischl, GnHans-Juergen M, Schwaiger M, Molls M, Piert M. Hypoxia imaging with FAZAPET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007; 69: 541–551.
78. Chapman JD, Zanzonico P, Ling CC. On measuring of hypoxia in individual tumors with radiolabeled agents. J. Nucl. Med. 2001; 42: 653–655.
79. Tannock IF, Minchinton AI. Drug penetration in solid tumours. Nature Reviews/Cancer 2006; 6: 583–592.
80. Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Initial results of hypoxia imaging using 1-a-D-(5-deoxy-5[18F]-fluoroarabinofuranosyl)-2- nitroimidazole (18F-FAZA). Eur. J. Nucl. Med. Mol. Imaging, 2009.
81. Urtasun RC, Parliament MB, McEwan AJ, Mercer JR, Mannan RH, Wiebe LI, Morin C, Chapman JD. Measurement of hypoxia in human tumors by SPECT imaging of iodoazomycin arabinoside. Brit. J. Cancer. 1996; 74: S209–S212.
82. Thorwarth D, Eschmann S-M, Scheiderbaur J, Paulsen F, Alber M. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in headand- neck cancer. BMC Cancer 2005; 5: 152.
83. Cascieri JJ, Graham MM, Rasey JS. Amodelling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data. Med. Phys. 1995; 22: 1127–1139.
84. Evans SM, Jenkins KW, Jenkins WT, Dilling T, Judy KD, Schrlau A, Judkins A, Hahn SM, Koch CJ. Imaging and analytical methods for the evaluation of vasculature and hypoxia in human brain tumors. Radiat. Res. 2008; 170: 677–690.
85. Koch CJ, Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles. Adv. Exptl. Med. Biol. 2003; 510: 285–292.
86. Salmon, HW, Siemann DW. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radioth. Oncol. 2004; 73: 359–366.
87. Komar G, Seppänen P, Eskola O, Lindholm P, Grönroos JT, Forsback S, Sipilä H, Evans SM, Solin O, Minn H. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J. Nuc. Med. 2008; 49: 1–8.
88. Hicks KO, Fleming Y, Siim BG, Koch CJ, Wilson W. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Rad. Onc. Biol. Phys. 1998; 42: 641–649.
89. Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischi G, Machulla H-J, Bares R. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J. Nuc. Med. 2005; 46: 253–260.
90. Groshar D, McEwan AJ, Parliament MB, Urtasun RC, Golberg LE, Hoskinson M, Mercer JR, Mannan RH, Wiebe LI, Chapman JD. Imaging tumor hypoxia and tumor perfusion. J. Nuc. Med. 1993; 34: 885–888.
91. Lehtio K, Eskola O, Viljanen T, Oikonen V, Gronroos T, Sillanmaki L, Grenman R, Minn H. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int. J. Rad. Oncol. Biol. Phys. 2004; 35: 975–980.
92. Sutherland RM. Cell and environmental interactions in tumor microregions: the multicellular spheroid model. Science 1988; 240: 177–184.
93. Brown DM, Gonsalez-Mendez R, Brown JM. Factors influencing intracellular uptake and radiosensitization by 2-nitroimidazoles in vitro. Radiat. Res. 1983; 93: 492–505.
94. John E, Green MA. Structure-activity relationships for metal-labeled blood flow tracers: comparison of ketoaldehyde bis(thiosemicarbazonato)copperII derivatives. J. Med. Chem. 1990; 33: 1764–1770.
95. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J. Nuc. Med. 1999; 40: 177–183.
96. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetylbis(N4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J. Nuc. Med. 2000; 42: 655–661.
97. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response — a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55: 1233–1238.
98. Arbeit JM, Brown JM, Chao KSC, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, Hill RP, Koch CJ, Krishna MC, Krohn KA, Lewis JS, Mason RP, Melillo G, Padhani AR, Powis G, Rajendran JG, Reba R, Robinson SP, Semenza GL, Swartz HM, Vaupel P, Yang D. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol. 2006; 82: 699–757.
99. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegal BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylsemicarbazone). J. Nuc. Med. 2008; 49: 2001–2005.
100. McCarthy DW, Bass LA, Cutler PD, Shefer RE, Klinkowstein RE, Herrero P, Lewis JS, Cutler CS, Anderson CJ, Welch MJ. High purity production and potential applications of Copper-60 and Copper-61. Nuc. Med. & Biol. 1999; 26: 351–358.
101. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996; 56: 4509–4515.
102. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tissue oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996; 56: 941–943.
103. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J. Biol. Chem. 1993; 268: 21513–21518.
104. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr. Opin. Genetics Dev. 2001c; 11: 293–299.
105. Moon EJ, Brizel DM, Chi J-TA, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antiox. Redox. Signal. 2007; 9: 1237–1294.
106. Semenza GL. Targeting HIF-1 for cancer therapy. Nature Reviews 2003; 3: 721–732.
107. Rijken PEJ W, PETers JPW, van der Kogel AJ. Quantitative analysis of varying profiles of hypoxia in relation to functional vessels in different human glioma xenograft lines. Radiat. Res. 2002; 157: 626–632.
108. Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Brit. J. Radiol. 1979; 52: 650–656.
109. Chaplin DJ, Durand RE, Olive PL. Acute hypoxia in tumors: implications for modifiers of radiation effects. Int. J. Radiat. Biol. Phys. 1986; 12: 1279–1282.
110. Dewhirst MW, Kimura H, Rehmus SW, Braun RD, Papahadjopoulos D, Hong K, Secomb TW. Microvascular studies on the origins of perfusion-limited hypoxia. Brit. J. Cancer 1996; 27: S247–S251.
111. Dewhirst MW, Ong ET, Braun RD, Smith B, Klitzman B, Evans SM, Wilson D. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Brit. J. Cancer 1999; 79: 1717–1722.
112. Hoffman EJ, Phelps ME. Positron emission tomography. Principles and quantitation. Positron Emission Tomography and Autoradiography. Principles and Application for the Brain and Heart. 1986; 237–286.
113. Koch CJ, Shuman AL, Jenkins WT, Kachur AV, Karp JS, Freifelder R, Dolbier WR, Evans SM. The radiation response of cells from 9L gliosarcoma tumors is correlated with [F18]-EF5 uptake. Int. J. Radiat. Biol. 2009. In Press.
114. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-nitroimidazole (EF5) binding predicts radiation sensitivity in individual 9L subcutaneous tumors. Cancer Res. 1996; 56: 405–411.
115. Kavanagh MC, Tsang V, Chow S, Koch C, Hedley D, Minkin S, Hil LRP. A comparison in individual murine tumors of techniques for measuring oxygen levels. Int. J. Radiat. Oncol. Biol. Phys. 1999; 44: 1137–1146.
116. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott R. Evaluation of copper(II)-pyruvaldehyde bis(N4-methylsemicarbazone) for tissue blood flow measurement using a trapped tracer method. J. Nuc. Med. 1994; 21: 336–341.
117. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nuc. Med. 1997; 38: 1155–1160.
118. Brown JM. The hypoxic cell: a target for selective cancer therapy eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999; 59: 5863–5870.
119. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. A novel approach to overcome hypoxic tumor resistance: Cu-ATSMguided intensity-modulated radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2001; 49: 1171–1182.
120. Flynn RT, Bowen SR, Bentzen SM, Mackie TR, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys. in Med. and Biol. 2008; 53: 4153–4167.